Ratislav Bahleda

736 total citations
31 papers, 458 citations indexed

About

Ratislav Bahleda is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Ratislav Bahleda has authored 31 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cancer Research, 13 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Ratislav Bahleda's work include Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Fibroblast Growth Factor Research (6 papers). Ratislav Bahleda is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Fibroblast Growth Factor Research (6 papers). Ratislav Bahleda collaborates with scholars based in France, United States and Spain. Ratislav Bahleda's co-authors include Jean‐Charles Soria, Christophe Massard, Éric Deutsch, Vincent Ribrag, Carlos Gomez‐Roca, Jean‐Pierre Armand, Gilles Vassal, Clarisse Dromain, Nicolas Magné and Jean‐Pierre Pignon and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

Ratislav Bahleda

30 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ratislav Bahleda France	12	218	168	128	114	64	31	458
C. Le Tourneau France	12	213 1.0×	108 0.6×	142 1.1×	72 0.6×	47 0.7×	41	399
V. Papadimitrakopoulou United States	13	313 1.4×	223 1.3×	304 2.4×	110 1.0×	53 0.8×	41	606
Jason B. Litten United States	9	132 0.6×	202 1.2×	87 0.7×	87 0.8×	73 1.1×	21	537
Patricia Tresca France	13	350 1.6×	141 0.8×	190 1.5×	127 1.1×	23 0.4×	26	542
Joseph Gibbons United States	10	193 0.9×	102 0.6×	180 1.4×	71 0.6×	61 1.0×	17	491
Mohamed A. Gouda United States	13	228 1.0×	166 1.0×	166 1.3×	219 1.9×	25 0.4×	58	546
Xuyang Song United States	9	331 1.5×	78 0.5×	155 1.2×	62 0.5×	39 0.6×	26	506
A. Van Oosterom Belgium	11	268 1.2×	228 1.4×	209 1.6×	124 1.1×	62 1.0×	28	572
Sasja F. Mulder Netherlands	12	253 1.2×	265 1.6×	340 2.7×	130 1.1×	43 0.7×	38	669
K. Nathan Sankar United States	14	269 1.2×	124 0.7×	170 1.3×	80 0.7×	28 0.4×	41	526

Countries citing papers authored by Ratislav Bahleda

Since Specialization

Citations

This map shows the geographic impact of Ratislav Bahleda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ratislav Bahleda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ratislav Bahleda more than expected).

Fields of papers citing papers by Ratislav Bahleda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ratislav Bahleda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ratislav Bahleda. The network helps show where Ratislav Bahleda may publish in the future.

Co-authorship network of co-authors of Ratislav Bahleda

This figure shows the co-authorship network connecting the top 25 collaborators of Ratislav Bahleda. A scholar is included among the top collaborators of Ratislav Bahleda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ratislav Bahleda. Ratislav Bahleda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smolenschi, Cristina, Antoine Hollebecque, Alice Boilève, et al.. (2023). PD-29 Could molecular profiling be helpful in daily practice in the treatment of anal carcinoma?. Annals of Oncology. 34. S13–S13. 1 indexed citations

Gazzah, Anas, Ratislav Bahleda, Antoine Hollebecque, et al.. (2023). Profile and outcome of cancer patients enrolled in contemporary phase I trials. European Journal of Cancer. 188. 1–7. 2 indexed citations

Ibrahim, Rebecca, Tarek Assi, Rita Khoury, et al.. (2023). Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives. Cancer Treatment Reviews. 123. 102675–102675. 4 indexed citations

Facchinetti, Fabio, Ratislav Bahleda, Loïc Verlingue, et al.. (2021). 34MO Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials. Annals of Oncology. 32. S14–S15. 1 indexed citations

Hollebecque, Antoine, Ratislav Bahleda, Éric Deutsch, et al.. (2015). Communication en oncologie dans le cadre d’essais thérapeutiques de phase I : mise en œuvre et évaluation d’un programme de formation. Bulletin du Cancer. 102(2). 174–181.

Verstovšek, Srđan, Ronald Hoffman, John Mascarenhas, et al.. (2014). A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leukemia Research. 39(2). 157–163. 25 indexed citations

Pautier, Patricia, Clara Locher, Caroline Robert, et al.. (2013). Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. OncoImmunology. 2(2). e23079–e23079. 15 indexed citations

Lévy, Antonin, Carlos Gomez‐Roca, Christophe Massard, et al.. (2013). Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials. Oncology Research and Treatment. 36(6). 357–362. 3 indexed citations

Hollebecque, Antoine, Éric Deutsch, C. Massard, et al.. (2013). A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. Investigational New Drugs. 31(6). 1530–1538. 23 indexed citations

10.

Massard, Christophe, Nadia Amellal, Yvette Drew, et al.. (2012). Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors. Investigational New Drugs. 31(3). 623–630. 14 indexed citations

11.

Gomez‐Roca, Carlos, Ludovic Lacroix, Christophe Massard, et al.. (2011). Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Annals of Oncology. 23(5). 1301–1306. 32 indexed citations

12.

Gomez‐Roca, Carlos, Serge Koscielny, Vincent Ribrag, et al.. (2011). Tumour growth rates and RECIST criteria in early drug development. European Journal of Cancer. 47(17). 2512–2516. 64 indexed citations

13.

Soria, J.C., Filippo de Braud, R. Cereda, et al.. (2011). First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). TPS149–TPS149. 13 indexed citations

14.

Dolly, Saoirse, Joan Albanell, Françoise Kraeber‐Bodéré, et al.. (2011). First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3006–3006. 4 indexed citations

15.

Calvo, Emiliano, A. W. Tolcher, María Jesús Cancelo Hidalgo, et al.. (2010). Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).. Journal of Clinical Oncology. 28(15_suppl). 3026–3026. 5 indexed citations

16.

Soria, J.C., Udai Banerji, Ratislav Bahleda, et al.. (2010). 365 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour. European Journal of Cancer Supplements. 8(7). 115–116. 1 indexed citations

17.

Massard, C., Carlos Gomez‐Roca, Ratislav Bahleda, et al.. (2010). Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of aryl-hydrocarbon receptor-mediated aminoflavone prodrug AFP464 in advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2561–2561. 1 indexed citations

18.

Loriot, Yohann, Charles Ferté, Carlos Gomez‐Roca, et al.. (2009). Pemetrexed-Induced Pneumonitis: A Case Report. Clinical Lung Cancer. 10(5). 364–366. 7 indexed citations

19.

LoRusso, Patricia, Tina Guthrie, Jean‐Charles Soria, et al.. (2009). Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(12_Supplement). C197–C197. 4 indexed citations

20.

Italiano, Antoîne, Christophe Massard, Ratislav Bahleda, et al.. (2007). Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Annals of Oncology. 19(4). 787–792. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact